All In Biotech

Drug Trial Radar · NCT02625974

A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi

Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease

Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

330

Actual

Start

Jan 27, 2016

Primary completion

Jul 25, 2018

Study completion Aug 10, 2021

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Dec 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat children who have an infectious disease caused by the parasite Trypanosoma cruzi (Chagas' disease). Chagas'disease is an inflammatory, infectious disease caused by the parasite Trypanosoma cruzi. This parasite is mainly spread by insects called triatomine bug. If Chagas' disease is left untreated, it can later cause serious heart and digestive problems. The study treatment nifurtimox has been used for more than 50 years to treat Chagas' disease. When used early after infection, it kills the parasite. In people who have long-term Chagas' disease, it's no longer possible to kill the parasite. However, nifurtimox may help slow the progression of the disease and its most serious complications. Nifurtimox was developed for use in adults only, but has also been used in children (off-label) for over 40 years. Currently it is available for doctors to give to adults and to children. However, there are not enough data about nifurtimox in children. The main purpose of this study is to learn how well nifurtimox works in children aged 8 months to less than 18 years with Chagas' disease. To answer this, the researchers will compare the amount of antibodies against the parasite Trypanosoma cruzi in the serum (fluid from blood without the clotting factors) between children treated with nifurtimox for 60 days with untreated children from the past (control group): * 12 months and * 4 years after the end of treatment. The data for the control group will come from 2 previous studies conducted in children.

Conditions

  • Chagas Disease

Interventions

  • Nifurtimox (Lampit, BAYA2502)Drug

    For pediatric participants with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses. For pediatric participants with body weight \> 40 kg: 8 - 10 mg/kg/day in three divided doses. 60 days or 30 days of nifurtimox treatment

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects)Time frame: At 12 months post-treatment
  2. Part 2 - Incidence Rate of Seronegative Conversion in Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.Time frame: Subjects participating in Part 2 were followed up for another 3 years, for a total follow-up period of 4 years after end of nifurtimox treatment in Part 1

Locations

25 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Corrientes, Argentina

  • Site not named

    Formosa, Argentina

  • Site not named

    La Rioja, Argentina

  • Site not named

    Mendoza, Argentina

  • Site not named

    Mendoza, Argentina

  • Site not named

    Salta, Argentina

  • Site not named

    Salta, Argentina

  • Site not named

    San Juan, Argentina

  • Site not named

    San Miguel de Tucumán, Argentina

  • Site not named

    Santiago del Estero, Argentina

  • Site not named

    La Plata, Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    San Salvador de Jujuy, Jujuy Province, Argentina

  • Site not named

    Posadas, Misiones Province, Argentina

  • Site not named

    Rosario, Santa Fe Province, Argentina

  • Site not named

    Cochabamba, Bolivia

  • Site not named

    Punata, Bolivia

  • Site not named

    Tarija, Bolivia

  • Site not named

    Soledad, Atlántico, Colombia

  • Site not named

    Yopal, Casanare Department, Colombia

  • Site not named

    Santa Marta, Magdalena Department, Colombia

  • Site not named

    Floridablabca, Santander Department, Colombia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.